Deprescribing in Outpatient Internal Medicine Practices

NCT07226960 | Recruiting

• 1 other identifier: IRB00137786
• Study Type: interventional
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to evaluate the impact of pharmacist-led medication reviews and deprescribing or de-escalation interventions on reducing the number of medications, falls, and hospitalizations, and improvement in quality of life in geriatric patients.

Conditions

Deprescribing

Keywords

Polypharmacy; medication regimens; medication reviews; geriatric patients

Outcome Measures

Primary Outcomes (1)

• Change in number of medications

  Change in number of medications

  Month 3

Secondary Outcomes (5)

• Change in Medication Appropriateness Index scores

  Month 3

• Change in Quality of life scores

  Month 3

• Number of documented falls

  Month 3

• Number of documented hospitalizations

  Month 3

• Number of documented visits to Primary Care Physician office

  Month 3

Other Outcomes (1)

• Number of Pharmacist interventions

  Month 3

Study Arms (2)

medication review - deprescribing / de-escalation may occur

EXPERIMENTAL

Internal medicine providers and PharmDs will identify patients for whom a medication review and potential deprescribing / de-escalation intervention may be beneficial, and make recommendations to adjust therapy as appropriate.

Behavioral: medication review

historical controls

NO INTERVENTION

No contact or intervention will be made with these patients, only retrospective chart review to gather data such as number of medications, hospitalizations, and falls. Patients included in the historical control arm will be matched to the intervention group based on sex, age, and number of medications as much as possible. The goal will be to include 50 patients in both the intervention and control arms.

Interventions

medication review BEHAVIORAL

Internal medicine providers and PharmDs will identify patients for whom a medication review and potential deprescribing / de-escalation intervention may be beneficial.

Also known as: potential deprescribing / de-escalation

medication review - deprescribing / de-escalation may occur

Eligibility Criteria

• Age: 75 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Older Adult (65+)

You may qualify if:

• years or older
• taking 6 or more medications

You may not qualify if:

• patients in hospice or palliative care
• in Skilled Nursing Facility
• receiving cancer/oncology treatment

Sponsors & Collaborators

• Wake Forest University Health Sciences: lead

Study Sites (1)

Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States

RECRUITING

MeSH Terms

Interventions

Medication Review

Intervention Hierarchy (Ancestors)

Medication Systems; Organization and Administration; Health Services Administration; Patient Care Management

Study Officials

• Julia Clements, PharmD

  Wake Forest University Health Sciences

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Anna Gambrell, PharmD

CONTACT

980-505-4718; anna.gambrell@advocatehealth.org

Kayla Marvin, PharmD

CONTACT

704-403-8650; kayla.marvin@advocatehealth.org

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: SUPPORTIVE CARE
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Prospective, mixed methods, investigator-initiated pilot quality improvement analysis

Study Record Dates

• First Submitted: November 10, 2025
• First Posted: November 12, 2025
• Study Start: November 12, 2025
• Primary Completion: May 1, 2026
• Study Completion: May 1, 2026
• Last Updated: May 4, 2026

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will not share

Locations

US (1)